ID   CD11B_HUMAN             Reviewed;         795 AA.
AC   P21127; B7ZVY7; J3KTL7; J3QR29; J3QR44; O95265; Q12817; Q12818; Q12819;
AC   Q12820; Q12822; Q8N530; Q9NZS5; Q9UBJ0; Q9UBQ1; Q9UBR0; Q9UNY2; Q9UP57;
AC   Q9UP58; Q9UP59;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   28-MAR-2018, sequence version 4.
DT   12-OCT-2022, entry version 229.
DE   RecName: Full=Cyclin-dependent kinase 11B;
DE            EC=2.7.11.22;
DE   AltName: Full=Cell division cycle 2-like protein kinase 1;
DE            Short=CLK-1;
DE   AltName: Full=Cell division protein kinase 11B;
DE   AltName: Full=Galactosyltransferase-associated protein kinase p58/GTA;
DE   AltName: Full=PITSLRE serine/threonine-protein kinase CDC2L1;
DE   AltName: Full=p58 CLK-1;
GN   Name=CDK11B; Synonyms=CDC2L1, CDK11, PITSLREA, PK58;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 7), AND FUNCTION.
RC   TISSUE=Liver;
RX   PubMed=2217177; DOI=10.1073/pnas.87.19.7467;
RA   Bunnell B.A., Heath L.S., Adams D.E., Lahti J.M., Kidd V.J.;
RT   "Increased expression of a 58-kDa protein kinase leads to changes in the
RT   CHO cell cycle.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:7467-7471(1990).
RN   [2]
RP   ERRATUM OF PUBMED:2217177, AND SEQUENCE REVISION.
RX   PubMed=2006197; DOI=10.1073/pnas.88.6.2612d;
RA   Bunnell B.A., Heath L.S., Adams D.E., Lahti J.M., Kidd V.J.;
RL   Proc. Natl. Acad. Sci. U.S.A. 88:2612-2612(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 7), AND VARIANT GLN-601.
RC   TISSUE=Hematopoietic;
RX   PubMed=1639388; DOI=10.1016/0888-7543(92)90132-c;
RA   Eipers P.G., Lahti J.M., Kidd V.J.;
RT   "Structure and expression of the human p58clk-1 protein kinase chromosomal
RT   gene.";
RL   Genomics 13:613-621(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS SV1; 2; 3; 8 AND SV11), VARIANT
RP   CYS-57, TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=8195233; DOI=10.1016/s0021-9258(17)40749-6;
RA   Xiang J., Lahti J.M., Grenet J.A., Easton J.B., Kidd V.J.;
RT   "Molecular cloning and expression of alternatively spliced PITSLRE protein
RT   kinase isoforms.";
RL   J. Biol. Chem. 269:15786-15794(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS SV1; SV4; SV5; SV9; SV10
RP   AND SV11), AND TISSUE SPECIFICITY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=9750192; DOI=10.1101/gr.8.9.929;
RA   Gururajan R., Lahti J.M., Grenet J.A., Easton J., Gruber I., Ambros P.F.,
RA   Kidd V.J.;
RT   "Duplication of a genomic region containing the Cdc2L1-2 and MMP21-22 genes
RT   on human chromosome 1p36.3 and their linkage to D1Z2.";
RL   Genome Res. 8:929-939(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SV11).
RC   TISSUE=Placenta;
RA   Govindan M.V., Warriar N.;
RL   Submitted (JUL-1999) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SV1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH RNPS1.
RX   PubMed=9580558; DOI=10.1242/jcs.111.11.1495;
RA   Loyer P., Trembley J.H., Lahti J.M., Kidd V.J.;
RT   "The RNP protein, RNPS1, associates with specific isoforms of the p34cdc2-
RT   related PITSLRE protein kinases in vivo.";
RL   J. Cell Sci. 111:1495-1506(1998).
RN   [10]
RP   ALTERNATIVE INITIATION (ISOFORM 7), AND INDUCTION.
RX   PubMed=10882096; DOI=10.1016/s1097-2765(00)80239-7;
RA   Cornelis S., Bruynooghe Y., Denecker G., Van Huffel S., Tinton S.,
RA   Beyaert R.;
RT   "Identification and characterization of a novel cell cycle-regulated
RT   internal ribosome entry site.";
RL   Mol. Cell 5:597-605(2000).
RN   [11]
RP   INTERACTION WITH RANBP9, AUTOPHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=14511641; DOI=10.1016/j.bbrc.2003.08.116;
RA   Mikolajczyk M., Shi J., Vaillancourt R.R., Sachs N.A., Nelson M.;
RT   "The cyclin-dependent kinase 11(p46) isoform interacts with RanBPM.";
RL   Biochem. Biophys. Res. Commun. 310:14-18(2003).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CCNL1 AND SFRS7.
RX   PubMed=12501247; DOI=10.1074/jbc.m210057200;
RA   Hu D., Mayeda A., Trembley J.H., Lahti J.M., Kidd V.J.;
RT   "CDK11 complexes promote pre-mRNA splicing.";
RL   J. Biol. Chem. 278:8623-8629(2003).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH PAK1.
RX   PubMed=12624090; DOI=10.1074/jbc.m300818200;
RA   Chen S., Yin X., Zhu X., Yan J., Ji S., Chen C., Cai M., Zhang S., Zong H.,
RA   Hu Y., Yuan Z., Shen Z., Gu J.;
RT   "The C-terminal kinase domain of the p34cdc2-related PITSLRE protein kinase
RT   (p110C) associates with p21-activated kinase 1 and inhibits its activity
RT   during anoikis.";
RL   J. Biol. Chem. 278:20029-20036(2003).
RN   [14]
RP   PHOSPHORYLATION AT SER-115.
RX   PubMed=15883043; DOI=10.1016/j.bbrc.2005.04.078;
RA   Feng Y., Qi W., Martinez J., Nelson M.A.;
RT   "The cyclin-dependent kinase 11 interacts with 14-3-3 proteins.";
RL   Biochem. Biophys. Res. Commun. 331:1503-1509(2005).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-595, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [17]
RP   PHOSPHORYLATION AT SER-482 AND THR-488 BY CDK7.
RX   PubMed=16327805; DOI=10.1038/nsmb1028;
RA   Larochelle S., Batliner J., Gamble M.J., Barboza N.M., Kraybill B.C.,
RA   Blethrow J.D., Shokat K.M., Fisher R.P.;
RT   "Dichotomous but stringent substrate selection by the dual-function Cdk7
RT   complex revealed by chemical genetics.";
RL   Nat. Struct. Mol. Biol. 13:55-62(2006).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH CCNL1 AND CCNL2.
RX   PubMed=18216018; DOI=10.1074/jbc.m708188200;
RA   Loyer P., Trembley J.H., Grenet J.A., Busson A., Corlu A., Zhao W.,
RA   Kocak M., Kidd V.J., Lahti J.M.;
RT   "Characterization of cyclin L1 and L2 interactions with CDK11 and splicing
RT   factors: influence of cyclin L isoforms on splice site selection.";
RL   J. Biol. Chem. 283:7721-7732(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-594 AND THR-595, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-589 AND THR-595, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-595, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-595, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-595, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   INTERACTION WITH MYO18A.
RX   PubMed=25965346; DOI=10.1371/journal.pone.0126576;
RA   Yang L., Carrillo M., Wu Y.M., DiAngelo S.L., Silveyra P., Umstead T.M.,
RA   Halstead E.S., Davies M.L., Hu S., Floros J., McCormack F.X.,
RA   Christensen N.D., Chroneos Z.C.;
RT   "SP-R210 (Myo18A) isoforms as intrinsic modulators of macrophage priming
RT   and activation.";
RL   PLoS ONE 10:E0126576-E0126576(2015).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-641, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [28]
RP   INTERACTION WITH HHV-1 TRANSCRIPTIONAL REGULATOR ICP22 (MICROBIAL
RP   INFECTION).
RX   PubMed=34696162; DOI=10.3390/vaccines9101054;
RA   Isa N.F., Bensaude O., Aziz N.C., Murphy S.;
RT   "HSV-1 ICP22 Is a Selective Viral Repressor of Cellular RNA Polymerase II-
RT   Mediated Transcription Elongation.";
RL   Vaccines (Basel) 9:0-0(2021).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-57; TRP-201; LEU-414; ALA-452; VAL-463;
RP   SER-506; GLN-601; ASN-641 AND VAL-670.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Plays multiple roles in cell cycle progression, cytokinesis
CC       and apoptosis. Involved in pre-mRNA splicing in a kinase activity-
CC       dependent manner. Isoform 7 may act as a negative regulator of normal
CC       cell cycle progression. {ECO:0000269|PubMed:12501247,
CC       ECO:0000269|PubMed:12624090, ECO:0000269|PubMed:18216018,
CC       ECO:0000269|PubMed:2217177}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.22;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.22;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Phosphorylation at Thr-448 or Tyr-449 inactivates
CC       the enzyme, while phosphorylation at Thr-595 activates it.
CC       {ECO:0000250|UniProtKB:P06493}.
CC   -!- SUBUNIT: Cleaved isoform SV9 (p110C) binds to the serine/threonine
CC       kinase PAK1 and RANBP9. p110C interacts with RNPS1. Isoform 7, but not
CC       isoform SV9, nor its cleavage product p110C, interacts with CCND3.
CC       Interacts with CCNL1 and CCNL2. Forms complexes with pre-mRNA-splicing
CC       factors, including at least SRSF1, SRSF2 and SRSF7/SLU7. Interacts with
CC       isoform 5 of MYO18A (PubMed:25965346). {ECO:0000269|PubMed:12501247,
CC       ECO:0000269|PubMed:12624090, ECO:0000269|PubMed:14511641,
CC       ECO:0000269|PubMed:25965346, ECO:0000269|PubMed:9580558}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human herpes virus 1
CC       (HHV-1) transcriptional regulator ICP22. {ECO:0000269|PubMed:34696162}.
CC   -!- INTERACTION:
CC       P21127; O00303: EIF3F; NbExp=3; IntAct=EBI-1298, EBI-711990;
CC       P21127; Q13153: PAK1; NbExp=4; IntAct=EBI-1298, EBI-1307;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=10;
CC       Name=SV9; Synonyms=CDK11-p110;
CC         IsoId=P21127-1; Sequence=Displayed;
CC       Name=SV1; Synonyms=Alpha 2-1;
CC         IsoId=P21127-2; Sequence=VSP_008280;
CC       Name=2; Synonyms=Alpha 2-2;
CC         IsoId=P21127-3; Sequence=VSP_008278, VSP_008279, VSP_008280;
CC       Name=3; Synonyms=Alpha 1;
CC         IsoId=P21127-4; Sequence=VSP_008276;
CC       Name=SV4;
CC         IsoId=P21127-5; Sequence=VSP_008275;
CC       Name=SV5;
CC         IsoId=P21127-6; Sequence=VSP_008273, VSP_008277, VSP_008278,
CC                                  VSP_008280;
CC       Name=8; Synonyms=Alpha 2-3;
CC         IsoId=P21127-8; Sequence=VSP_008278, VSP_008280;
CC       Name=SV10;
CC         IsoId=P21127-9; Sequence=VSP_008273, VSP_008277, VSP_008280;
CC       Name=SV11; Synonyms=Alpha 2-4;
CC         IsoId=P21127-10; Sequence=VSP_008274, VSP_008280;
CC       Name=7; Synonyms=CDK11-p58;
CC         IsoId=P21127-12; Sequence=VSP_018834;
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously. Some evidence of isoform-
CC       specific tissue distribution. {ECO:0000269|PubMed:8195233,
CC       ECO:0000269|PubMed:9750192}.
CC   -!- INDUCTION: Isoform 7 is induced in G2/M phase of the cell cycle.
CC       {ECO:0000269|PubMed:10882096}.
CC   -!- PTM: During FAS- or TNF-induced apoptosis, isoform SV9 is cleaved by
CC       caspases to produce p110C, a fragment that contains the C-terminal
CC       kinase domain.
CC   -!- PTM: Phosphorylation at Ser-115 creates a binding site for 14-3-3
CC       proteins. p110C can be autophosphorylated.
CC       {ECO:0000269|PubMed:15883043, ECO:0000269|PubMed:16327805}.
CC   -!- MISCELLANEOUS: Duplicated gene. CDK11A and CDK11B encode almost
CC       identical protein kinases of 110 kDa that contain at their C-termini
CC       the open reading frame of a smaller 58 kDa isoform which is expressed
CC       following IRES-mediated alternative initiation of translation.
CC   -!- MISCELLANEOUS: [Isoform 7]: Produced by alternative initiation at Met-
CC       357 of isoform SV9 via an internal ribosomal entry site (IRES).
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. CDC2/CDKX subfamily. {ECO:0000305}.
CC   -!- CAUTION: Many references talk about 'p110 isoforms' but it is not yet
CC       known if this refers to CDK11A and/or CDK11B or one/some of the
CC       isoforms of each. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB59449.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAC83664.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=AAF36538.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M37712; AAA36406.1; -; mRNA.
DR   EMBL; M88563; AAB59449.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; M88553; AAB59449.1; JOINED; Genomic_DNA.
DR   EMBL; M88554; AAB59449.1; JOINED; Genomic_DNA.
DR   EMBL; M88555; AAB59449.1; JOINED; Genomic_DNA.
DR   EMBL; M88558; AAB59449.1; JOINED; Genomic_DNA.
DR   EMBL; M88559; AAB59449.1; JOINED; Genomic_DNA.
DR   EMBL; M88560; AAB59449.1; JOINED; Genomic_DNA.
DR   EMBL; M88561; AAB59449.1; JOINED; Genomic_DNA.
DR   EMBL; M88562; AAB59449.1; JOINED; Genomic_DNA.
DR   EMBL; U04815; AAA19581.1; -; mRNA.
DR   EMBL; U04816; AAA19582.1; -; mRNA.
DR   EMBL; U04817; AAA19583.1; -; mRNA.
DR   EMBL; U04818; AAA19584.1; -; mRNA.
DR   EMBL; U04824; AAA19586.1; -; mRNA.
DR   EMBL; AF067512; AAC72077.1; -; mRNA.
DR   EMBL; AF067513; AAC72078.1; -; mRNA.
DR   EMBL; AF067514; AAC72079.1; -; mRNA.
DR   EMBL; AF067515; AAC72080.1; -; mRNA.
DR   EMBL; AF067516; AAC72081.1; -; mRNA.
DR   EMBL; AF067517; AAC72082.1; -; mRNA.
DR   EMBL; AF080683; AAC83662.1; -; Genomic_DNA.
DR   EMBL; AF080685; AAC83662.1; JOINED; Genomic_DNA.
DR   EMBL; AF080686; AAC83662.1; JOINED; Genomic_DNA.
DR   EMBL; AF080687; AAC83662.1; JOINED; Genomic_DNA.
DR   EMBL; AF080688; AAC83662.1; JOINED; Genomic_DNA.
DR   EMBL; AF092429; AAC83662.1; JOINED; Genomic_DNA.
DR   EMBL; AF092430; AAC83662.1; JOINED; Genomic_DNA.
DR   EMBL; AF080678; AAC83662.1; JOINED; Genomic_DNA.
DR   EMBL; AF080679; AAC83662.1; JOINED; Genomic_DNA.
DR   EMBL; AF080680; AAC83662.1; JOINED; Genomic_DNA.
DR   EMBL; AF080681; AAC83662.1; JOINED; Genomic_DNA.
DR   EMBL; AF080682; AAC83662.1; JOINED; Genomic_DNA.
DR   EMBL; AF080683; AAC83663.1; -; Genomic_DNA.
DR   EMBL; AF080685; AAC83663.1; JOINED; Genomic_DNA.
DR   EMBL; AF080686; AAC83663.1; JOINED; Genomic_DNA.
DR   EMBL; AF080687; AAC83663.1; JOINED; Genomic_DNA.
DR   EMBL; AF080688; AAC83663.1; JOINED; Genomic_DNA.
DR   EMBL; AF092429; AAC83663.1; JOINED; Genomic_DNA.
DR   EMBL; AF092430; AAC83663.1; JOINED; Genomic_DNA.
DR   EMBL; AF080678; AAC83663.1; JOINED; Genomic_DNA.
DR   EMBL; AF080679; AAC83663.1; JOINED; Genomic_DNA.
DR   EMBL; AF080680; AAC83663.1; JOINED; Genomic_DNA.
DR   EMBL; AF080681; AAC83663.1; JOINED; Genomic_DNA.
DR   EMBL; AF080682; AAC83663.1; JOINED; Genomic_DNA.
DR   EMBL; AF080683; AAC83664.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AF080685; AAC83664.1; JOINED; Genomic_DNA.
DR   EMBL; AF080686; AAC83664.1; JOINED; Genomic_DNA.
DR   EMBL; AF080687; AAC83664.1; JOINED; Genomic_DNA.
DR   EMBL; AF080688; AAC83664.1; JOINED; Genomic_DNA.
DR   EMBL; AF092429; AAC83664.1; JOINED; Genomic_DNA.
DR   EMBL; AF092430; AAC83664.1; JOINED; Genomic_DNA.
DR   EMBL; AF080678; AAC83664.1; JOINED; Genomic_DNA.
DR   EMBL; AF080679; AAC83664.1; JOINED; Genomic_DNA.
DR   EMBL; AF080680; AAC83664.1; JOINED; Genomic_DNA.
DR   EMBL; AF080681; AAC83664.1; JOINED; Genomic_DNA.
DR   EMBL; AF080682; AAC83664.1; JOINED; Genomic_DNA.
DR   EMBL; AF080683; AAC83665.1; -; Genomic_DNA.
DR   EMBL; AF080685; AAC83665.1; JOINED; Genomic_DNA.
DR   EMBL; AF080686; AAC83665.1; JOINED; Genomic_DNA.
DR   EMBL; AF080687; AAC83665.1; JOINED; Genomic_DNA.
DR   EMBL; AF080688; AAC83665.1; JOINED; Genomic_DNA.
DR   EMBL; AF092429; AAC83665.1; JOINED; Genomic_DNA.
DR   EMBL; AF092430; AAC83665.1; JOINED; Genomic_DNA.
DR   EMBL; AF080678; AAC83665.1; JOINED; Genomic_DNA.
DR   EMBL; AF080679; AAC83665.1; JOINED; Genomic_DNA.
DR   EMBL; AF080680; AAC83665.1; JOINED; Genomic_DNA.
DR   EMBL; AF080681; AAC83665.1; JOINED; Genomic_DNA.
DR   EMBL; AF080682; AAC83665.1; JOINED; Genomic_DNA.
DR   EMBL; AF080683; AAC83666.1; -; Genomic_DNA.
DR   EMBL; AF092430; AAC83666.1; JOINED; Genomic_DNA.
DR   EMBL; AF080678; AAC83666.1; JOINED; Genomic_DNA.
DR   EMBL; AF080679; AAC83666.1; JOINED; Genomic_DNA.
DR   EMBL; AF080680; AAC83666.1; JOINED; Genomic_DNA.
DR   EMBL; AF080681; AAC83666.1; JOINED; Genomic_DNA.
DR   EMBL; AF080682; AAC83666.1; JOINED; Genomic_DNA.
DR   EMBL; AF174497; AAF36538.1; ALT_INIT; mRNA.
DR   EMBL; FO704657; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC140714; AAI40715.1; -; mRNA.
DR   EMBL; BC171773; AAI71773.1; -; mRNA.
DR   CCDS; CCDS72682.1; -. [P21127-9]
DR   CCDS; CCDS72683.1; -. [P21127-1]
DR   CCDS; CCDS72684.1; -. [P21127-2]
DR   PIR; A38282; A38282.
DR   PIR; B54024; B54024.
DR   PIR; E54024; E54024.
DR   PIR; F54024; F54024.
DR   PIR; H54024; H54024.
DR   PIR; T09568; T09568.
DR   RefSeq; NP_001278274.1; NM_001291345.1. [P21127-8]
DR   RefSeq; NP_001778.2; NM_001787.2. [P21127-1]
DR   RefSeq; NP_277021.2; NM_033486.2. [P21127-2]
DR   RefSeq; NP_277022.1; NM_033487.2. [P21127-5]
DR   RefSeq; NP_277024.2; NM_033489.2. [P21127-9]
DR   RefSeq; NP_277025.1; NM_033490.2. [P21127-10]
DR   RefSeq; XP_016858415.1; XM_017002926.1. [P21127-3]
DR   AlphaFoldDB; P21127; -.
DR   SMR; P21127; -.
DR   BioGRID; 107421; 117.
DR   ComplexPortal; CPX-345; Cyclin L2-CDK11B(p58) complex. [P21127-12]
DR   ComplexPortal; CPX-346; Cyclin L1-CDK11B(p58) complex. [P21127-12]
DR   ComplexPortal; CPX-348; Cyclin L1-CDK11B(p110) complex. [P21127-1]
DR   ComplexPortal; CPX-349; Cyclin L2-CDK11B(p110) complex. [P21127-1]
DR   CORUM; P21127; -.
DR   IntAct; P21127; 32.
DR   MINT; P21127; -.
DR   STRING; 9606.ENSP00000464036; -.
DR   BindingDB; P21127; -.
DR   ChEMBL; CHEMBL5808; -.
DR   DrugCentral; P21127; -.
DR   GlyGen; P21127; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P21127; -.
DR   PhosphoSitePlus; P21127; -.
DR   BioMuta; CDK11B; -.
DR   DMDM; 34978359; -.
DR   EPD; P21127; -.
DR   jPOST; P21127; -.
DR   MassIVE; P21127; -.
DR   MaxQB; P21127; -.
DR   PaxDb; P21127; -.
DR   PeptideAtlas; P21127; -.
DR   PRIDE; P21127; -.
DR   ProteomicsDB; 53836; -. [P21127-1]
DR   ProteomicsDB; 53837; -. [P21127-10]
DR   ProteomicsDB; 53838; -. [P21127-12]
DR   ProteomicsDB; 53839; -. [P21127-2]
DR   ProteomicsDB; 53840; -. [P21127-3]
DR   ProteomicsDB; 53841; -. [P21127-4]
DR   ProteomicsDB; 53842; -. [P21127-5]
DR   ProteomicsDB; 53843; -. [P21127-6]
DR   ProteomicsDB; 53844; -. [P21127-8]
DR   ProteomicsDB; 53845; -. [P21127-9]
DR   Antibodypedia; 62301; 125 antibodies from 20 providers.
DR   DNASU; 984; -.
DR   Ensembl; ENST00000340677.9; ENSP00000464016.2; ENSG00000248333.9. [P21127-9]
DR   Ensembl; ENST00000341832.11; ENSP00000463048.2; ENSG00000248333.9. [P21127-2]
DR   Ensembl; ENST00000407249.7; ENSP00000464036.2; ENSG00000248333.9. [P21127-1]
DR   GeneID; 984; -.
DR   KEGG; hsa:984; -.
DR   MANE-Select; ENST00000341832.11; ENSP00000463048.2; NM_033486.3; NP_277021.2. [P21127-2]
DR   UCSC; uc031tmi.2; human.
DR   CTD; 984; -.
DR   DisGeNET; 984; -.
DR   GeneCards; CDK11B; -.
DR   HGNC; HGNC:1729; CDK11B.
DR   HPA; ENSG00000248333; Low tissue specificity.
DR   MIM; 176873; gene.
DR   neXtProt; NX_P21127; -.
DR   OpenTargets; ENSG00000248333; -.
DR   PharmGKB; PA26262; -.
DR   VEuPathDB; HostDB:ENSG00000248333; -.
DR   eggNOG; KOG0663; Eukaryota.
DR   GeneTree; ENSGT00940000158459; -.
DR   InParanoid; P21127; -.
DR   OMA; MLDNWDD; -.
DR   OrthoDB; 925637at2759; -.
DR   PhylomeDB; P21127; -.
DR   TreeFam; TF101035; -.
DR   BRENDA; 2.7.11.22; 2681.
DR   PathwayCommons; P21127; -.
DR   Reactome; R-HSA-380270; Recruitment of mitotic centrosome proteins and complexes.
DR   SignaLink; P21127; -.
DR   SIGNOR; P21127; -.
DR   BioGRID-ORCS; 984; 43 hits in 260 CRISPR screens.
DR   ChiTaRS; CDK11B; human.
DR   GeneWiki; CDC2L1; -.
DR   GenomeRNAi; 984; -.
DR   Pharos; P21127; Tchem.
DR   PRO; PR:P21127; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P21127; protein.
DR   Bgee; ENSG00000248333; Expressed in sural nerve and 93 other tissues.
DR   ExpressionAtlas; P21127; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0004693; F:cyclin-dependent protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; NAS:UniProtKB.
DR   GO; GO:0000278; P:mitotic cell cycle; NAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IC:ComplexPortal.
DR   GO; GO:0051726; P:regulation of cell cycle; IC:ComplexPortal.
DR   GO; GO:0001558; P:regulation of cell growth; IEP:UniProtKB.
DR   GO; GO:0046605; P:regulation of centrosome cycle; IC:ComplexPortal.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; NAS:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0050684; P:regulation of mRNA processing; IDA:UniProtKB.
DR   CDD; cd07843; STKc_CDC2L1; 1.
DR   InterPro; IPR045267; CDK11/PITSLRE_STKc.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative initiation; Alternative splicing; Apoptosis; ATP-binding;
KW   Cell cycle; Cytoplasm; Isopeptide bond; Kinase; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..795
FT                   /note="Cyclin-dependent kinase 11B"
FT                   /id="PRO_0000024311"
FT   DOMAIN          438..723
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          17..412
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          733..795
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        17..83
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        98..118
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        119..251
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        262..288
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        300..362
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        363..382
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        562
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         444..452
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         467
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         47
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P24788"
FT   MOD_RES         72
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P24788"
FT   MOD_RES         115
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15883043"
FT   MOD_RES         283
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P24788"
FT   MOD_RES         482
FT                   /note="Phosphoserine; by CDK7"
FT                   /evidence="ECO:0000269|PubMed:16327805"
FT   MOD_RES         488
FT                   /note="Phosphothreonine; by CDK7"
FT                   /evidence="ECO:0000269|PubMed:16327805"
FT   MOD_RES         589
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   MOD_RES         594
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         595
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         751
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P24788"
FT   MOD_RES         752
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P24788"
FT   CROSSLNK        641
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         1..356
FT                   /note="Missing (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:2217177"
FT                   /id="VSP_018834"
FT   VAR_SEQ         1..269
FT                   /note="Missing (in isoform SV4)"
FT                   /evidence="ECO:0000303|PubMed:9750192"
FT                   /id="VSP_008275"
FT   VAR_SEQ         1..217
FT                   /note="Missing (in isoform SV11)"
FT                   /evidence="ECO:0000303|PubMed:8195233,
FT                   ECO:0000303|PubMed:9750192, ECO:0000303|Ref.6"
FT                   /id="VSP_008274"
FT   VAR_SEQ         1..34
FT                   /note="Missing (in isoform SV5 and isoform SV10)"
FT                   /evidence="ECO:0000303|PubMed:16710414,
FT                   ECO:0000303|PubMed:9750192"
FT                   /id="VSP_008273"
FT   VAR_SEQ         2..335
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:8195233"
FT                   /id="VSP_008276"
FT   VAR_SEQ         35..37
FT                   /note="LKN -> MSQ (in isoform SV5 and isoform SV10)"
FT                   /evidence="ECO:0000303|PubMed:9750192"
FT                   /id="VSP_008277"
FT   VAR_SEQ         110..119
FT                   /note="Missing (in isoform 2, isoform SV5 and isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:8195233,
FT                   ECO:0000303|PubMed:9750192"
FT                   /id="VSP_008278"
FT   VAR_SEQ         165
FT                   /note="R -> RGNDGVCLFR (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:8195233"
FT                   /id="VSP_008279"
FT   VAR_SEQ         252..265
FT                   /note="GEARPAPAQKPAQL -> V (in isoform SV1, isoform 2,
FT                   isoform SV5, isoform 8, isoform SV10 and isoform SV11)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:16710414, ECO:0000303|PubMed:8195233,
FT                   ECO:0000303|PubMed:9750192, ECO:0000303|Ref.6"
FT                   /id="VSP_008280"
FT   VARIANT         57
FT                   /note="R -> C (in dbSNP:rs752740049)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:8195233"
FT                   /id="VAR_041958"
FT   VARIANT         93
FT                   /note="R -> W (in dbSNP:rs1059831)"
FT                   /id="VAR_057775"
FT   VARIANT         109
FT                   /note="R -> C (in dbSNP:rs1059830)"
FT                   /id="VAR_062199"
FT   VARIANT         201
FT                   /note="R -> W (in dbSNP:rs1557687207)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041959"
FT   VARIANT         414
FT                   /note="S -> L (in dbSNP:rs1241694892)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041960"
FT   VARIANT         452
FT                   /note="V -> A"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_045577"
FT   VARIANT         463
FT                   /note="I -> V"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041961"
FT   VARIANT         506
FT                   /note="G -> S"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_045578"
FT   VARIANT         601
FT                   /note="L -> Q (in dbSNP:rs200190129)"
FT                   /evidence="ECO:0000269|PubMed:1639388,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041962"
FT   VARIANT         641
FT                   /note="K -> N (in dbSNP:rs1059815)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041963"
FT   VARIANT         670
FT                   /note="A -> V (in dbSNP:rs1059811)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041964"
FT   CONFLICT        97
FT                   /note="A -> V (in Ref. 4; AAA19582/AAA19583/AAA19586 and 5;
FT                   AAC72077/AAC72079/AAC72080/AAC72081/AAC83662/AAC83664/AAC83665)"
FT   CONFLICT        109
FT                   /note="Missing (in Ref. 4; AAA19582/AAA19583 and 5;
FT                   AAC72079)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        126
FT                   /note="E -> K (in Ref. 4; AAA19582/AAA19583/AAA19586)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        258
FT                   /note="P -> R (in Ref. 5; AAC72080)"
FT   CONFLICT        320
FT                   /note="S -> T (in Ref. 6; AAF36538)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        324..326
FT                   /note="Missing (in Ref. 4;
FT                   AAA19582/AAA19583/AAA19584/AAA19586 and 6; AAF36538)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        411..412
FT                   /note="PA -> LP (in Ref. 3; AAB59449)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        436
FT                   /note="E -> D (in Ref. 3; AAB59449)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        560
FT                   /note="H -> Q (in Ref. 6; AAF36538)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        567
FT                   /note="N -> T (in Ref. 6; AAF36538)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        678
FT                   /note="E -> R (in Ref. 4;
FT                   AAA19582/AAA19581/AAA19583/AAA19584 and 6; AAF36538)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        694
FT                   /note="D -> E (in Ref. 3; AAB59449)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        697
FT                   /note="F -> C (in Ref. 6; AAF36538)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        712
FT                   /note="I -> L (in Ref. 3; AAB59449)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        715
FT                   /note="E -> Q (in Ref. 3; AAB59449)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        792
FT                   /note="S -> R (in Ref. 6; AAF36538)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   795 AA;  92620 MW;  8CCB0E688E66DF47 CRC64;
     MGDEKDSWKV KTLDEILQEK KRRKEQEEKA EIKRLKNSDD RDSKRDSLEE GELRDHRMEI
     TIRNSPYRRE DSMEDRGEED DSLAIKPPQQ MSRKEKAHHR KDEKRKEKRR HRSHSAEGGK
     HARVKEKERE HERRKRHREE QDKARREWER QKRREMAREH SRRERDRLEQ LERKRERERK
     MREQQKEQRE QKERERRAEE RRKEREARRE VSAHHRTMRE DYSDKVKASH WSRSPPRPPR
     ERFELGDGRK PGEARPAPAQ KPAQLKEEKM EERDLLSDLQ DISDSERKTS SAESSSAESG
     SGSEEEEEEE EEEEEEGSTS EESEEEEEEE EEEEEETGSN SEEASEQSAE EVSEEEMSED
     EERENENHLL VVPESRFDRD SGESEEAEEE VGEGTPQSSA LTEGDYVPDS PALSPIELKQ
     ELPKYLPALQ GCRSVEEFQC LNRIEEGTYG VVYRAKDKKT DEIVALKRLK MEKEKEGFPI
     TSLREINTIL KAQHPNIVTV REIVVGSNMD KIYIVMNYVE HDLKSLMETM KQPFLPGEVK
     TLMIQLLRGV KHLHDNWILH RDLKTSNLLL SHAGILKVGD FGLAREYGSP LKAYTPVVVT
     LWYRAPELLL GAKEYSTAVD MWSVGCIFGE LLTQKPLFPG KSEIDQINKV FKDLGTPSEK
     IWPGYSELPA VKKMTFSEHP YNNLRKRFGA LLSDQGFDLM NKFLTYFPGR RISAEDGLKH
     EYFRETPLPI DPSMFPTWPA KSEQQRVKRG TSPRPPEGGL GYSQLGDDDL KETGFHLTTT
     NQGASAAGPG FSLKF
//
